scholarly journals Molecular Characterization of a Nondemyelinating Variant of Daniel’s Strain of Theiler’s Virus Isolated from a Persistently Infected Glioma Cell Line

1998 ◽  
Vol 72 (2) ◽  
pp. 1262-1269 ◽  
Author(s):  
Xiaoqi Lin ◽  
Shigeru Sato ◽  
Amy K. Patick ◽  
Larry R. Pease ◽  
Raymond P. Roos ◽  
...  

ABSTRACT Wild-type Daniel’s strain of Theiler’s virus (wt-DA) induces a chronic demyelination in susceptible mice which is similar to multiple sclerosis. A variant of wt-DA (designated DA-P12) generated during the 12th passage of persistent infection of a G26-20 glioma cell line failed to persist and induce demyelination in SJL/J mice. To identify the determinants responsible for this change in phenotype, we sequenced the capsid coding sequence (nucleotides [nt] 2991 to 3994) and found three mutations in VP1: residues 99 (Gly to Ser), 100 (Gly to Asp), and 103 (Asn to Lys). To study the role of these mutations in neurovirulence and demyelination, we prepared a recombinant virus, DAP-1C-2A/DA, with replacement of wt-DA nt 2991 to 3994 with the corresponding region of DA-P12, and viruses with individual point mutations at VP1 residues 99(Ser), 100(Asp), and 103(Lys). DAP-1C-2A/DA and viruses with a mutation at VP1 residue 99 or 100 (but not 103) completely attenuated the ability of wt-DA to induce demyelination. Failure to induce demyelination was not due to a general failure in growth, since DA-P12 and other mutant viruses lysed L-2 cells in vitro as effectively as wt-DA. The change in disease phenotype was independent of the specific B- or T-cell immune recognition because a decrease in the neurovirulence of mutant viruses was observed in neonatal mice and immune-deficient RAG1 −/− mice. This difference in neurovirulence is not the complete explanation for the failure of DA-P12 to demyelinate, since virus with a mutation at residue 103(Lys) had decreased neurovirulence but did induce demyelination. Therefore, point mutation at VP1 residue 99 or 100 altered the ability of wt-DA to demyelinate, perhaps related to a disruption in interaction between virus and receptor on certain neural cells.

BMC Cancer ◽  
2008 ◽  
Vol 8 (1) ◽  
Author(s):  
Camila ML Machado ◽  
Rafael Y Ikemori ◽  
Tatiana Q Zorzeto ◽  
Ana CMA Nogueira ◽  
Suse DS Barbosa ◽  
...  

2014 ◽  
Vol 16 (suppl 2) ◽  
pp. ii30-ii30 ◽  
Author(s):  
L. Mercurio ◽  
A. Ricci ◽  
S. Cecchetti ◽  
A. Pacella ◽  
F. Podo ◽  
...  

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Michael T. C. Poon ◽  
Morgan Bruce ◽  
Joanne E. Simpson ◽  
Cathal J. Hannan ◽  
Paul M. Brennan

Abstract Background Malignant glioma cell line models are integral to pre-clinical testing of novel potential therapies. Accurate prediction of likely efficacy in the clinic requires that these models are reliable and consistent. We assessed this by examining the reporting of experimental conditions and sensitivity to temozolomide in glioma cells lines. Methods We searched Medline and Embase (Jan 1994-Jan 2021) for studies evaluating the effect of temozolomide monotherapy on cell viability of at least one malignant glioma cell line. Key data items included type of cell lines, temozolomide exposure duration in hours (hr), and cell viability measure (IC50). Results We included 212 studies from 2789 non-duplicate records that reported 248 distinct cell lines. The commonest cell line was U87 (60.4%). Only 10.4% studies used a patient-derived cell line. The proportion of studies not reporting each experimental condition ranged from 8.0–27.4%, including base medium (8.0%), serum supplementation (9.9%) and number of replicates (27.4%). In studies reporting IC50, the median value for U87 at 24 h, 48 h and 72 h was 123.9 μM (IQR 75.3–277.7 μM), 223.1 μM (IQR 92.0–590.1 μM) and 230.0 μM (IQR 34.1–650.0 μM), respectively. The median IC50 at 72 h for patient-derived cell lines was 220 μM (IQR 81.1–800.0 μM). Conclusion Temozolomide sensitivity reported in comparable studies was not consistent between or within malignant glioma cell lines. Drug discovery science performed on these models cannot reliably inform clinical translation. A consensus model of reporting can maximise reproducibility and consistency among in vitro studies.


2008 ◽  
Vol 319 (1-2) ◽  
pp. 61-68 ◽  
Author(s):  
Luci Bavaresco ◽  
Andressa Bernardi ◽  
Elizandra Braganhol ◽  
Angélica Regina Cappellari ◽  
Liliana Rockenbach ◽  
...  

2015 ◽  
Vol 25 (4) ◽  
pp. 753-757 ◽  
Author(s):  
Subhadeep Banerjee ◽  
Anjan Chattopadhyay ◽  
Arnab Banerjee ◽  
Meera Haridas ◽  
Praveen Saini ◽  
...  

2009 ◽  
Vol 72 (4) ◽  
pp. 310-316 ◽  
Author(s):  
Camila Maria Longo Machado ◽  
Tatiane Queiroz Zorzeto ◽  
Juares E. Romero Bianco ◽  
Renata Giardini Rosa ◽  
Selma Candelaria Genari ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document